Avation Medical

Avation Medical operates at the intersection of medical devices, digital health, wearables, and neuromodulation. Its clearest market differentiation is the Vivally System: a wearable, FDA-cleared device designed to deliver overactive bladder therapy at home in 30-minute sessions three times per week. That approach contrasts with treatment pathways that may require clinic visits, pharmaceuticals, or more invasive procedures, although the company’s commercial position depends on sustained clinical evidence, reimbursement access, patient adherence, and physician adoption. The company has attracted strategic and specialist healthcare investors, including Asahi Kasei, Medtronic, Arboretum Ventures, Angelini Ventures, and Shangbay Capital. Its 2024 ISO 13485 certification and dedicated market-access leadership suggest an emphasis on moving beyond device development toward regulated commercialization. Avation Medical’s strongest identifiable competitive asset is the combination of a regulated wearable product, non-invasive neuromodulation, and an at-home care model focused on a defined condition rather than a broad consumer wellness market.

Avation Medical shows a progression from early device development toward commercialization. The company was founded in 2016 and recorded a 2020 venture round of $12,924,999, followed by a $22 million Series C announced on Feb 1, 2024. The company’s financing history is listed as three rounds totaling $34,924,999, with a Series D recorded on Mar 20, 2026; the available round-level amounts contain an inconsistency that limits precise financing analysis. Operationally, 2024 was an inflection point: Avation Medical obtained ISO 13485 certification, added market-access and product-marketing leaders, and publicly promoted the Vivally System for overactive bladder. The 2026 appointment of co-founder Manish Vaishya as CEO represents another transition, shifting leadership toward commercialization and growth. Its trajectory therefore appears to be defined more clearly by financing, quality-system readiness, executive hiring, and product commercialization than by publicly measurable workforce growth.